Tretinoin (ATRA)
Vesanoid · Retinoid (differentiating agent)
Differentiation syndrome → capillary leak and AKI.
Lumakras · Sotor
KRAS G12C inhibitor · approved 2021 · 6 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The first KRAS-G12C inhibitor — renal injury is largely a rat-specific metabolite story, with sparse human signal.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Clinically significant nephrotoxicity is uncommon and case-level in humans (the dominant on-target/off-tumor toxicity is hepatotoxicity). Proximal tubular toxicity is prominent in rats via a reactive mercapturate-pathway metabolite. Human renal incidence is not well quantified.Source: Werner et al., Toxicol Appl Pharmacol 2021 (rat mechanism)
Acute AKI during the first weeks to months of therapy, typically tracking GI toxicity.
Distilled from: “When AKI occurs, it is acute during the first weeks–months of therapy, typically tracking GI toxicity.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Proximal-tubular necrosis localized to the outer stripe of the outer medulla, dose- and time-dependent and tracking urinary tubular-injury biomarkers, driven by a reactive mercapturate/beta-lyase pathway metabolite (mechanistic, Sprague-Dawley rat; species-dependent, informs the human proximal-tubular signal). PMID 34004237 (opens PubMed in a new tab)
First-in-class covalent inhibitor that binds the mutant cysteine-12 of KRAS G12C and locks the oncoprotein in its inactive GDP-bound state, blocking downstream RAF-MEK-ERK (MAPK) signaling in KRAS-G12C–mutated non-small cell lung cancer (NSCLC) and colorectal cancer.
Vasculature / Endothelium
Glomerular & peritubular capillaries
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 3,470 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
824 of 3,470 reports
Reported with hospitalization
705 of 3,470 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Sotorasib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Vesanoid · Retinoid (differentiating agent)
Differentiation syndrome → capillary leak and AKI.
Elzonris · IL-3 immunotoxin
Capillary-leak syndrome → AKI.
Mektovi · MEK inhibitor
Creatinine rise; rhabdomyolysis reports.
Oncaspar · Enzyme (asparaginase)
Rare AKI; pancreatitis- and thrombosis-mediated.
Talvey · Bispecific (GPRC5D×CD3)
CRS-related AKI — emerging.
Tecvayli · Bispecific (BCMA×CD3)
CRS-associated AKI in myeloma — emerging signal.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.